```html

Yellow Plaque Sarcoidosis – A Comprehensive Medical Guide

Overview

Yellow plaque sarcoidosis is a distinct cutaneous manifestation of systemic sarcoidosis. It appears as smooth, raised, yellow‑brown plaques, most often on the face (especially the nose and cheeks), forearms, or shins. Although the skin lesions themselves are benign, they signal that granulomatous inflammation is occurring elsewhere in the body, most commonly in the lungs, lymph nodes, and eyes.

Who it affects

• Adults aged 20‑40 years are most frequently diagnosed, but cases occur from childhood through the elderly.
• Women are slightly more likely than men to develop cutaneous sarcoidosis (≈55 % female).
• Higher incidence in Black/African‑American and Scandinavian populations; in the United States, the overall prevalence of sarcoidosis is about 10–20 per 100,000, with skin involvement in 20‑35 % of those patients. Yellow plaque lesions represent roughly 5‑10 % of cutaneous cases.

Because sarcoidosis is a systemic disease, the presence of yellow plaques warrants a thorough evaluation for internal organ involvement.

Symptoms

Cutaneous signs dominate the symptom profile of yellow plaque sarcoidosis, but patients may also experience systemic complaints related to underlying organ disease.

Skin‑related symptoms

• Yellow‑brown plaques: Soft, non‑painful, often 0.5–3 cm in diameter; may coalesce into larger patches.
• Location: Nose, malar cheeks, forehead, forearms, shins, and occasionally the scalp.
• Texture: Smooth, slightly raised, sometimes with a “apple‑jelly” hue when pressed (diascopy).
• Itchiness: Mild to moderate pruritus in up to 30 % of patients.
• Healing: Lesions can persist for months to years; spontaneous regression is uncommon without therapy.

Systemic symptoms (reflecting sarcoidosis elsewhere)

• Persistent dry cough or shortness of breath.
• Chest pain or tightness.
• Fatigue and malaise.
• Weight loss or loss of appetite.
• Joint pain or swelling (often non‑erosive arthropathy).
• Eye irritation, redness, or blurred vision (uveitis).
• Generalized fever or night sweats (less common).

Causes and Risk Factors

The exact trigger for sarcoidosis—including the yellow plaque variant—is unknown, but research points to an abnormal immune response to an unidentified antigen in genetically susceptible individuals.

Potential causes

• Immune dysregulation: Overactive CD4⁺ T‑lymphocytes release cytokines (e.g., interferon‑γ, TNF‑α) that drive non‑caseating granuloma formation.
• Environmental exposures: Occupational dust (silica, beryllium), insecticides, and certain organic antigens have been implicated.
• Infectious agents: Mycobacteria, Propionibacterium acnes, and various viruses are under investigation as possible triggers.

Risk factors

• Family history of sarcoidosis or other autoimmune diseases.
• Being of Black, African‑American, or Northern European descent.
• Age between 20–40 years.
• Smoking is not a clear risk factor; some studies suggest a slightly lower incidence among smokers, but it does not protect against cutaneous disease.
• Occupational exposure to inorganic dusts or chemicals.

Diagnosis

Diagnosing yellow plaque sarcoidosis requires correlating clinical appearance with histopathology and evaluating for systemic involvement.

Step‑by‑step diagnostic pathway

1. Clinical examination: Dermatologist identifies characteristic yellow plaques; assesses distribution and any associated skin findings (e.g., lupus pernio, maculopapular lesions).
2. Skin biopsy:
   • Shows non‑caseating epithelioid granulomas without necrosis.
   • Special stains (AFB, PAS) are performed to exclude infections.
3. Laboratory tests:
   • Serum angiotensin‑converting enzyme (ACE) – elevated in ~60 % of active sarcoidosis.
   • Calcium level – hypercalcemia may be present.
   • Complete blood count, liver function tests – to screen for organ involvement.
4. Imaging:
   • Chest X‑ray (CXR) – bilateral hilar lymphadenopathy in ~90 % of systemic cases.
   • High‑resolution CT (HRCT) – more sensitive for parenchymal lung disease.
   • PET‑CT – identifies active granulomatous inflammation for treatment planning.
5. Organ‑specific assessments:
   • Pulmonary function tests (spirometry, DLCO).
   • Ophthalmologic exam – baseline slit‑lamp for uveitis.
   • Electrocardiogram (ECG) & echocardiogram if cardiac symptoms.

Diagnostic criteria*: Clinical picture + compatible biopsy + exclusion of other granulomatous diseases (e.g., tuberculosis, fungal infection).

Treatment Options

Treatment is individualized based on symptom severity, extent of skin disease, and presence of internal organ involvement. Many patients with isolated yellow plaques have a relatively indolent course and may be observed, while others need systemic therapy.

Topical & Local Therapies

• High‑potency topical steroids (clobetasol propionate 0.05 %): Applied twice daily for 4‑8 weeks can reduce plaque thickness.
• Intralesional corticosteroids (triamcinolone acetonide 10–20 mg/mL): Delivered directly into plaques for rapid flattening.
• Topical calcineurin inhibitors (tacrolimus 0.1 %): Useful for patients who cannot tolerate steroids.

Systemic Medications

• Oral corticosteroids (prednisone 20‑40 mg daily, tapered over 3–6 months): First‑line for extensive skin disease or concurrent pulmonary involvement.
• Antimetabolites:
  • Methotrexate 10‑25 mg weekly (folic acid supplementation).
  • Azathioprine 2‑2.5 mg/kg daily.
  Both are steroid‑sparing agents for long‑term control.
• Biologic therapy:
  • Infliximab (anti‑TNF‑α) 5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks.
  • Adalimumab (subcutaneous) 40 mg every other week.
  Reserved for refractory disease or severe organ involvement.
• Hydroxychloroquine 200‑400 mg daily: Beneficial for skin lesions and hypercalcemia; monitor retinal health.

Procedural Options

• Laser therapy (pulsed dye or CO₂) – improves texture and pigmentation after disease control.
• Phototherapy (narrow‑band UVB) – evidence for modest improvement in cutaneous sarcoidosis.
• Cryotherapy – rarely used, can cause scarring; considered only for isolated, stubborn plaques.

Lifestyle and Supportive Measures

• Quit smoking; avoid exposure to silica, beryllium, and other occupational dusts.
• Maintain adequate vitamin D and calcium intake, but monitor serum calcium when on steroids.
• Regular exercise to preserve lung capacity and overall stamina.
• Psychosocial support—skin lesions on the face can affect self‑esteem; counseling or support groups are beneficial.

Living with Yellow Plaque Sarcoidosis

While there is no cure, most people lead full lives with appropriate management.

Daily management tips

1. Skin care: Use gentle, fragrance‑free cleansers. Apply prescribed topical agents as directed; moisturize twice daily to reduce dryness.
2. Sun protection: UV exposure can exacerbate lesions; use broad‑spectrum SPF 30+ sunscreen and wear hats.
3. Medication adherence: Keep a medication diary; set alarms for weekly methotrexate or biweekly biologic infusions.
4. Monitoring: Record any new symptoms (cough, vision changes, chest pain) and report them promptly.
5. Regular follow‑up: Dermatology visits every 3–6 months; pulmonary or ophthalmology reviews based on organ involvement.
6. Emotional health: Join sarcoidosis patient groups (e.g., Sarcoidosis Foundation) for peer support.

Prevention

Because the exact cause is unknown, primary prevention is limited. However, modifiable risk factors can be addressed:

• Reduce occupational exposure to inorganic dusts and chemicals; use protective masks and ventilation.
• Maintain a healthy immune system through balanced nutrition, regular exercise, and adequate sleep.
• Screen high‑risk relatives (especially in families with known sarcoidosis) early if they develop unexplained skin lesions or respiratory symptoms.

Complications

If left untreated or inadequately controlled, yellow plaque sarcoidosis can be a marker for serious systemic disease.

• Pulmonary fibrosis: Progressive scarring leading to chronic dyspnea.
• Cardiac sarcoidosis: Arrhythmias, heart block, or heart failure.
• Ocular involvement: Uveitis can cause permanent visual loss.
• Hypercalcemia: May lead to kidney stones, nephrocalcinosis, or neuropsychiatric symptoms.
• Skin scarring or pigment changes after chronic plaques or aggressive treatment.
• Psychosocial impact: Depression or anxiety related to disfiguring facial lesions.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Sarcoidosis.” 2023; CDC. “Sarcoidosis Data and Statistics.” 2022; National Institutes of Health (NIH) – National Heart, Lung, and Blood Institute. “Sarcoidosis Treatment Guidelines.” 2024; WHO. “Rare Disease: Sarcoidosis.” 2023; Cleveland Clinic. “Cutaneous Sarcoidosis.” 2024; Peer‑reviewed articles from Chest and Journal of the American Academy of Dermatology (2022‑2024).

```